These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Fahr's Disease Presenting as Late-Onset Levodopa-Responsive Parkinsonism. Kumar N; Jog M Can J Neurol Sci; 2017 May; 44(3):322-323. PubMed ID: 28091340 [No Abstract] [Full Text] [Related]
5. Clinical and biochemical characterization of patients with early infantile onset of autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia. Opladen T; Hoffmann G; Hörster F; Hinz AB; Neidhardt K; Klein C; Wolf N Mov Disord; 2011 Jan; 26(1):157-61. PubMed ID: 20818608 [TBL] [Abstract][Full Text] [Related]
6. Carbidopa-levodopa therapy for movement disorders. Sohn DG; Hoerning E; Kaplan PE Arch Phys Med Rehabil; 1987 Oct; 68(10):745-6. PubMed ID: 3662785 [No Abstract] [Full Text] [Related]
7. [Treatment of patients with vascular parkinsonism with the preparations nakom and madopar]. Kamenetskiĭ VK Klin Med (Mosk); 1984 Apr; 62(4):112-6. PubMed ID: 6737958 [No Abstract] [Full Text] [Related]
8. Deletion in the tyrosine hydroxylase gene in a patient with a mild phenotype. Ormazabal A; Serrano M; Garcia-Cazorla A; Campistol J; Artuch R; Castro de Castro P; Barredo-Valderrama E; Armstrong J; Toma C; Cormand B Mov Disord; 2011 Jul; 26(8):1558-60. PubMed ID: 21465550 [No Abstract] [Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
10. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221 [TBL] [Abstract][Full Text] [Related]
11. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German Collaborative Study on Phenylketonuria. Weglage J; Ullrich K; Pietsch M; Fünders B; Güttler F; Harms E Pediatr Res; 1997 Sep; 42(3):378-84. PubMed ID: 9284280 [TBL] [Abstract][Full Text] [Related]
12. The nurse's role in clinical trials. Amyot D; Gray P; Demong C; Wilson W; Murphy D; Watson J; Duff J Can Nurse; 1996 Nov; 92(10):30-2. PubMed ID: 9095759 [TBL] [Abstract][Full Text] [Related]
13. Neonatal dopa-responsive extrapyramidal syndrome in twins with recessive GTPCH deficiency. Nardocci N; Zorzi G; Blau N; Fernandez Alvarez E; Sesta M; Angelini L; Pannacci M; Invernizzi F; Garavaglia B Neurology; 2003 Jan; 60(2):335-7. PubMed ID: 12552057 [TBL] [Abstract][Full Text] [Related]
14. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688 [TBL] [Abstract][Full Text] [Related]
15. Hemiballism and chorea in a patient with parkinsonism due to a multisystem degeneration. Steiger MJ; Pires M; Scaravilli F; Quinn NP; Marsden CD Mov Disord; 1992; 7(1):71-7. PubMed ID: 1557069 [TBL] [Abstract][Full Text] [Related]
16. [An acute onset extrapyramidal, pyramidal, and cerebellar syndrome with eye movement dysfunction]. Lippi A; Castelnovo G; Colombier L; Renard D Rev Neurol (Paris); 2015 Dec; 171(12):898-9. PubMed ID: 26318889 [No Abstract] [Full Text] [Related]
17. Arg(184)His mutant GTP cyclohydrolase I, causing recessive hyperphenylalaninemia, is responsible for dopa-responsive dystonia with parkinsonism: a case report. Kikuchi A; Takeda A; Fujihara K; Kimpara T; Shiga Y; Tanji H; Nagai M; Ichinose H; Urano F; Okamura N; Arai H; Itoyama Y Mov Disord; 2004 May; 19(5):590-3. PubMed ID: 15133828 [TBL] [Abstract][Full Text] [Related]
18. Post-stroke violent adventitial movement responsive to levo-dopa/carbi-dopa therapy. Frates EP; Burke DT; Chae H; Ahangar B Brain Inj; 2001 Oct; 15(10):911-6. PubMed ID: 11595087 [TBL] [Abstract][Full Text] [Related]
19. Management of the extrapyramidal manifestations of phenylketonuria with L-dopa. MacLeod MD; Munro JF; Ledingham JG; Farquhar JW Arch Dis Child; 1983 Jun; 58(6):457-8. PubMed ID: 6859941 [TBL] [Abstract][Full Text] [Related]
20. [Phenylketonuria with adult-onset neurological manifestation]. Ishimaru K; Tamasawa N; Baba M; Matsunaga M; Takebe K Rinsho Shinkeigaku; 1993 Sep; 33(9):961-5. PubMed ID: 8299276 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]